Broadway reopened, but final curtain call is coming for Big Pharma price gouging as House Ways and Means advances H.R. 3.
Welcome to the Week in Review.
1. ?Win In The House?
The House Ways and Means committee advanced the comprehensive provisions of H.R. 3 for inclusion in the $3.5 trillion reconciliation package this week. The committee’s favorable report ensures Medicare negotiation will be incorporated into the reconciliation package that moves to the House floor in coming weeks. “We applaud Chairman Richard Neal and Democratic members on the committee for standing up to Big Pharma and fighting for H.R. 3,” P4ADNow’s David Mitchell said. “Now the House and Senate must move forward with reconciliation to fulfill their promise to pass strong Medicare negotiation to lower drug prices on behalf of Americans.” — (Axios, Los Angeles Times)
2. Flip-Floppers
Right before the Ways and Means Committee advanced H.R. 3, three Democrats on the Energy and Commerce Committee — Reps. Peters, Rice, and Schrader — sided with Big Pharma and failed to support the drug pricing provisions. Their opposition is a speed bump on the way to reconciliation, but patients are holding them accountable with new ads that target Reps. Peters and Rice, who have an opportunity to vote in favor of the reconciliation package on the floor and advance the Medicare negotiation legislation. “It makes me so angry that members of Congress are choosing Big Pharma over patients,” says multiple sclerosis patient Therese Ball in the newads. “It’s unforgivable.” — (Common Dreams)
3.Ads On Ads
P4ADNow also launched another TV adthis week as part of its campaign to ensure patient voices are heard in the midst of multiple million-dollar Big Pharma campaigns full of lies and scare tactics. The new ad features Lynn Scarfuto, a retired nurse and cancer patient who faces a $15,000 price tag for her cancer medication, Imbruvica. “What happens to millions of Americans like me who can’t afford the drugs we so desperately need?” Lynn asks, “Congress, the opportunity to act is now.” Check out all our recent ads here. — (P4ADNow)
4. Sea To Shining Sea
New data collected by Data for Progress on behalf of P4ADNow and Protect Our Care shows overwhelming, bipartisan support for Medicare negotiation in every state and congressional district. The project surveyed 4,222 likely voters and found that 86% back reforms that give Medicare the power to negotiate lower drug prices; 81% believe prescription drug costs are “unreasonable”; and only 12% believe pharma’s argument that letting Medicare negotiate lower prices will harm innovation. The survey was modeled onto every congressional district in the country and all 50 states. It’s time to pass drug pricing reform. — (P4ADNow)
5. Voices Build For Lower Drug Prices
Elected officials and editorial boards are making their voices heard in support of allowing Medicare to negotiate lower drug prices. State and local officials in West Virginia say, “We have a once-in-a-generation opportunity to finally bring down drug prices for American families.” State Senator Troy Singleton agrees that, “Giving Medicare the power to negotiate for lower prescription drug prices for all Americans can save patients more than $150 billion and create $500 billion in savings for the federal government.” The New Jersey Star-Ledger warns the public not to be fooled by “dark money groups running a scaremongering ad campaign,” and explains that “lower drug prices also means lower insurance premiums and copays for patients who desperately need them.” The answer is clear: Let Medicare negotiate. — (WTRF, New Jersey Star-Ledger,New Jersey Star-Ledger)
Welcome to the Week in Review.
1. A Blueprint Forward
On Wednesday, the Department of Health and Human Services released a plan to lower drug prices, which includes allowing Medicare to negotiate lower prices, extending negotiated prices to the private sector, and investing in research to ensure continued innovation. The administration’s plan is bold, comprehensive, and exactly what patients across the country need at this moment. We’ll do everything we can to support the administration and Congress as they work to implement these important recommendations. — (Bloomberg Law)
2. “Listen To Patients”
To counter pharma’s continued scare tactics and falsehoods about Medicare negotiation, P4ADNow released a new TV ad this week calling out the drug industry’s lies and urging Congress to pass Medicare negotiation legislation. The new phase of the campaign, which also includes digital ads and congressional outreach from patient advocates, coincides with Congress’ work over the next few weeks to draft and mark up Medicare negotiation legislation to include in the reconciliation bill. “Don’t listen to the lies. Don’t listen to the threats. Don’t listen to the lobbyists. Listen to patients,” the ad tells Congress. “Medicare negotiation will help millions of patients get the innovation we need at prices we can afford … We’re counting on you to get it done.” — (Politico)
3. Medicare Negotiation Wins The Popularity Contest
A new survey shows that Medicare negotiation is the most popular provision in the president’s Build Back Better plan, with nearly 9 in 10 voters supporting the proposal. Americans continue to call for relief from Big Pharma’s abusive pricing practices. It’s time we put patients first. — (Navigator Research)
One more thing: Read these compelling viewpoints from a father of a cystic fibrosis patient in The Concord Monitor, two U.S. representatives in The Baltimore Sun, and an emergency room doctor in The Tucson Weekly about the need for Medicare negotiation.
Welcome to the Week in Review.
1. Negotiation *Improves* Access
On Monday, P4ADNow released a video featuring founder David Mitchell setting the record straight on how Medicare negotiation would improve access to drugs, contrary to Big Pharma’s lies that patient access will be harmed. The video complements P4AD’s recent fact check of six false claims in pharma-funded ads. “High prices limit access to medications people need right now. The Democratic plan would actually improve access by allowing Medicare to negotiate lower prices,” Mitchell says. “Nothing in the plan limits access to drugs. It’s another Big Pharma big lie.” — (P4ADNow)
2. Another Day, Another Lie
As congressional Democrats work to include drug pricing reforms like Medicare negotiation in the reconciliation package, pharma is pouring over $18 million in ad spending to protect its ability to dictate prices. In addition to the usual lies about access and innovation, the industry is now claiming that it should not be subjected to new regulations due to its role in developing COVID-19 vaccines. But it’s taxpayers who have largely bankrolled vaccine development — the U.S. government invested in research decades ago that led to the successful mRNA vaccines and has spent over $18 billion since the start of the pandemic on research, manufacturing, and distribution. It’s no surprise that yet another pharma claim fails to hold up to scrutiny. — (Politico)
3.In Case You Weren’t Sure
New polls show that about 4 out of 5 voters in Florida’s seventh congressional district and 9 out of 10 voters in New Jersey’s fifth district support allowing Medicare to negotiate lower drug prices. Insurers are also advocating for Medicare negotiation — the Alliance of Community Health Plans, a coalition of non-profit health insurers across the country, sent a letter to congressional leadership calling for the inclusion of Medicare negotiation in the reconciliation package. Voters, insurers, and employers are all united on this issue. It’s clear what Congress needs to do. — (Florida Politics, New Jersey Globe, Alliance of Community Health Plans)
One more thing: This week, Americans continued to write in support of Medicare negotiation, with powerful letters and op-eds from patients and advocates in Arizona, Nevada, Ohio, and West Virginia.
Welcome to the Week in Review.
1. Fact Or Pharma?
This week, P4AD released a fact check breaking down six misleading claims found in pharma-funded ads, including falsehoods about the non-interference clause and the impact of Medicare negotiation. Through front groups and its own lobby groups, the drug industry has bankrolled at least $18 million in ad spending this year to attack reforms that would allow Medicare to negotiate prices. But patients aren’t letting Big Pharma get away with the lies; it’s clear that we must pass Medicare negotiation to lower drug prices and improve access to medications patients need. — (P4AD)
2. “The Tides Are Finally Shifting”
In a new op-ed, Senator Klobuchar shares stories from Minnesotans who have struggled to afford prescription drugs and explains why this is the best opportunity in years to pass Medicare negotiation. “Not only does President Biden support [Medicare negotiation], he publicly endorsed it in a prime-time address and explicitly stated that he wanted to include it in the upcoming budget,” Senator Klobuchar writes. “Let’s use this political momentum and the power of 46 million seniors to finally get a fair deal.” — (Star Tribune)
Building on two national ads launched last weekend, P4ADNow launched a seven-figure ad buy on Tuesday thanking representatives across 12 House districts for supporting Medicare negotiation. The new ads, which counter Big Pharma’s recent attack ads against H.R. 3, will run through August recess and feature three patients who have struggled with high drug prices. “Right now, there’s a plan in Congress to let Medicare negotiate lower drug prices,” says the ad in Kansas’ third congressional district. “Sharice Davids supports it. Representative Davids, thank you.” — (Endpoints News)
2. “Put The Patients First”
In a new op-ed, Rep. Tim Ryan debunks pharma’s innovation myth and calls on his colleagues to pass H. R. 3 and allow Medicare to negotiate lower drug prices on behalf of Americans. “There’s never been a better time to deliver than now, as Congress contemplates a historic stimulus package that will reshape the economy and make long-overdue improvements in key areas,” he writes. “We must allow Medicare to negotiate lower drug prices so that Ohioans and all Americans get the affordable medications they need. Families and seniors can’t afford to wait.” — (Akron Beacon Journal)
3.A Profitable Pandemic
As the Biden administration announces plans for COVID-19 booster shots, vaccine makers Pfizer and Moderna are expected to rake in billions more in revenue. Analysts now forecast global vaccine sales of $74 billion for Pfizer and partner BioNTech and $35 billion for Moderna through 2022. Though the companies took billions of dollars in government funding to help bring the vaccines to market, Pfizer has raised its U.S. price from $19.50 to $24 per dose, and Moderna’s U.S. price has increased from $15 to $16.50 per dose. Americans continue to grapple with the uncertainty of this public health crisis, but one thing is clear: Drug companies are profiteering off a pandemic. — (The Wall Street Journal, Reuters)
One more thing:Watch HHS Secretary Xavier Becerra discuss the need for lower drug prices and how President Biden’s plan balances pricing and innovation in a segment for Yahoo! Finance.
He’s not Biden his time — the president wants Medicare negotiation now. Welcome to the Week in Review.
1. “We Have To Change This. And We Can.”
On Thursday, President Biden delivered an enthusiastic speechhighlighting how his Build Back Better agenda will call for Medicare to be allowed to negotiate lower prescription drug prices and extend negotiated prices to the private sector. The president urged Congress to move forward on legislation to deliver on his plan, which comprises a strong, comprehensive set of reforms that will deliver much-needed relief to Americans. “These prices put the squeeze on too many families and strip them of their dignity,” President Biden said. “Medicare is going to negotiate a fair price!” — (The Washington Post)
2. The Power Of Our Stories
President Biden featured patient advocate Gail deVore in his speech this week, and the White House released a video highlighting Gail’s one-on-one conversation with the president in the Oval Office. Gail lives with type 1 diabetes and uses Novolog insulin priced at $289 per vial. She was also invited to take over the White House Twitter account for a day. Gail, we are so proud of you for your tireless advocacy! Thank you for representingpatients across the country calling for immediate action to restore balance to our drug pricing system. — (The White House)
3.A Path Forward
This week, as Senate Democrats took the next step on their path toward a reconciliation package to deliver on the president’s Build Back Better agenda, it’s clear that Medicare negotiation is a critical piece of the plan. During the vote, a group of senators up for re-election led an amendmentemphasizing their commitment to ensuring the drug pricing policy is included in the package. In addition to lowering drug prices for patients, the policy would save hundreds of billions of dollars for taxpayers through direct drug savings as well as lower Part D premiums. This is the year we can get it done. — (Axios)
4. “It’s Killing Americans”
This weekend, P4ADNow will launch two new nationalads calling on Congress to lower drug prices by allowing Medicare negotiation. The ads, which will run throughout August recess, feature five patients who have struggled to afford their prescription drugs. The campaign also launched a website hub for patients to contact their members of Congress and write to their local publications in support of Medicare negotiation. “No one should have to drain their bank account for relief,” Ashley, a psoriatic arthritis patient, says in an ad. “The system is broken.” — (P4ADNow)
5. PhRMA’s Nose Grows
The Washington Post Fact Checker analyzed a new TV ad making the rounds from the drug industry lobby group PhRMA. The ad claims that the Medicare non-interference clause “protects access” to medicines and that negotiation would “make it harder for people on Medicare to get the medicines we need.” Fact Checker’s verdict? Three Pinocchios for misrepresenting Medicare negotiation as designed in H.R. 3 and for unsubstantiated fear-mongering. PhRMA is getting desperate as lawmakers work to hold the industry accountable — and now it shows it’s willing to lie to keep prices high. — (The Washington Post)
Climbing made its debut at the Olympics this week, but we’ve been watching drug prices ascend to new heights for years.
Welcome to the Week in Review.
1. Seniors Vote Yes On Medicare Negotiation
Across the country, seniors of all political affiliations agree: Medicare must be allowed to negotiate lower drug prices. A new poll from the Alliance for Retired Americans indicates that drug pricing reform is a winning issue, as seniors are more likely to vote for a candidate who supports Medicare negotiation. Right now, elected officials have the choice to side with patients or protect pharma’s unfettered pricing power. Voters are taking note. — (Alliance for Retired Americans)
2. Sounding Off: Letters For Lower Drug Prices
This week, lawmakers and Americans from all over the country wrote letters highlighting the need for drug pricing reform. Twelve senators signed a letter to Senate leadership asking to include Medicare negotiation in the reconciliation bill. In an op-ed, Delaware state Senator Jack Walsh urged Senators Chris Coons and Tom Carper to help pass legislation to allow Medicare to negotiate drug prices. And in letters to their local publications, constituents in Colorado, Rhode Island, and Florida discussed how lowering prices would help improve the lives of vulnerable communities, including seniors and people of color. It’s clear: Lowering drug prices is a top priority for Americans. — (Endpoints News, Delaware Business Times, Sentinel Colorado, Westerly Sun, The Ledger)
3.AbbVie’s Patent Abuses
While patients in other countries are benefiting from biosimilar competition to AbbVie’s top-selling drug Humira, Americans are forced to pay increasing prices that are five times what Europeans pay as AbbVie blocks competition with deals to delay biosimilars from entering the U.S. market until 2023. Just this year, AbbVie raised the price of Humira by 7.4 percent, continuing its trend of annual price hikes. Our broken patent system is breaking the bank for patients and taxpayers. We must reform it to incentivize innovation, not decades-long monopoly pricing. — (Axios)
If price hikes were an Olympic event, pharma would take gold, silver, and bronze.
Welcome to the Week in Review.
1. Putting The Brakes On Patent Abuse
In a unanimous, bipartisan vote, the Senate Judiciary Committee passeda package of four bills that would lower drug prices by addressing anticompetitive behavior from drug companies. The bills would curb patent abuses by designating product hopping, pay-for-delay deals, and sham citizen petitions as anticompetitive. We applaud the committee for protecting true innovation at prices patients can afford by advancing these bills, urge the Senate to pass the package, and call on Congress to continue the important work of lowering drug prices for Americans by allowing Medicare negotiation. — (P4ADNow)
2. 100 Years Later, A $100 Biosimilar
In the same week that the world marked 100 years of insulin, the FDA approved Semglee, the first interchangeable biosimilar to the long-acting insulin Lantus. It’s a step in the right direction, but Semglee’s $98 price tag still represents a 2,000 percent markup from a manufacturing cost of $4.50. We must ensure that all patients who depend on insulin have access to affordable medications by building a system that delivers reasonable profits and incentivizes competition for all forms of insulin. — (Axios)
3. Rep. Peters’ Flip Flop: Unforgivable
Back in 2019, Rep. Scott Peters (CA-52) supported H.R. 3, a bill that would allow Medicare to negotiate drug prices. But two years later, the congressman is now an outspoken opponent of the landmark legislation. Rep. Peters has filled his pockets with Big Pharma money and is actively opposing reform that would deliver much-needed relief to millions of patients across the country. Simply put, that’s unforgivable. — (Salon)
One more thing: This week, members of Congress highlighted pharma’s July price hikes and the need for Medicare to negotiate lower prices. Check it out here.
